View ValuationIndegene 향후 성장Future 기준 점검 4/6Indegene (는) 각각 연간 21.3% 및 15.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 20.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.4% 로 예상됩니다.핵심 정보21.3%이익 성장률20.45%EPS 성장률Life Sciences 이익 성장23.9%매출 성장률15.1%향후 자기자본이익률16.37%애널리스트 커버리지Low마지막 업데이트22 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Jul 19Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.72 (down from ₹17.15 in FY 2025). Revenue: ₹35.1b (up 24% from FY 2025). Net income: ₹4.01b (down 1.4% from FY 2025). Profit margin: 11% (down from 14% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.공고 • Jul 16+ 1 more updateIndegene Limited, Annual General Meeting, Aug 13, 2026Indegene Limited, Annual General Meeting, Aug 13, 2026, at 16:30 Indian Standard Time.공고 • Jul 10Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026공고 • Apr 21Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026Reported Earnings • Jan 30Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.공고 • Jan 22Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026Buy Or Sell Opportunity • Nov 24Now 21% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₹515. The fair value is estimated to be ₹426, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last year. Earnings per share has grown by 14%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 27% in the next 2 years.Reported Earnings • Nov 01Second quarter 2026 earnings released: EPS: ₹4.26 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.26 (up from ₹3.84 in 2Q 2025). Revenue: ₹8.24b (up 20% from 2Q 2025). Net income: ₹1.02b (up 11% from 2Q 2025). Profit margin: 12% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.공고 • Oct 23Indegene Limited to Report Q2, 2026 Results on Oct 30, 2025Indegene Limited announced that they will report Q2, 2026 results on Oct 30, 2025Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Non-Executive Independent Director Georgia Papathomas was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Aug 03First quarter 2026 earnings released: EPS: ₹4.86 (vs ₹3.79 in 1Q 2025)First quarter 2026 results: EPS: ₹4.86 (up from ₹3.79 in 1Q 2025). Revenue: ₹7.61b (up 13% from 1Q 2025). Net income: ₹1.16b (up 33% from 1Q 2025). Profit margin: 15% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.공고 • Jul 24Indegene Limited to Report Q1, 2026 Results on Jul 31, 2025Indegene Limited announced that they will report Q1, 2026 results on Jul 31, 2025공고 • Jun 06An undisclosed buyer agreed to acquire an unknown minority stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments.An undisclosed buyer agreed to acquire 10.19% stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments on June 3, 2025. The expected date of completion is June 06, 2025.Reported Earnings • Jun 01Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.공고 • May 29Indegene Limited, Annual General Meeting, Jun 26, 2025Indegene Limited, Annual General Meeting, Jun 26, 2025, at 16:30 Indian Standard Time.Reported Earnings • May 02Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.New Risk • Apr 30New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.공고 • Apr 21Indegene Limited to Report Q4, 2025 Results on Apr 28, 2025Indegene Limited announced that they will report Q4, 2025 results on Apr 28, 2025공고 • Feb 25Indegene Launches Cortex, A Fit-For-Purpose Generative Ai PlatformIndegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry Bengaluru, India and Princeton, US, February 24, 2025: Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement.Reported Earnings • Jan 31Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹4.59 (up from ₹4.45 in 3Q 2024). Revenue: ₹7.58b (up 10% from 3Q 2024). Net income: ₹1.10b (up 11% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 2.2%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.Recent Insider Transactions • Dec 29Chairman & CEO recently bought ₹10m worth of stockOn the 24th of December, Manish Gupta bought around 17k shares on-market at roughly ₹599 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹60m. This was Manish's only on-market trade for the last 12 months.Recent Insider Transactions • Dec 20Non-Executive Director recently bought ₹60m worth of stockOn the 17th of December, Rajesh Nair bought around 100k shares on-market at roughly ₹596 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹14m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Dec 07Insider recently sold ₹13m worth of stockOn the 5th of December, Viveksheel Ghai sold around 20k shares on-market at roughly ₹628 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹33m. Insiders have been net sellers, collectively disposing of ₹46m more than they bought in the last 12 months.Reported Earnings • Oct 29Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹3.84. Net income: ₹917.0m (up ₹917.0m from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.공고 • Oct 23Indegene Limited to Report Q2, 2025 Results on Oct 28, 2024Indegene Limited announced that they will report Q2, 2025 results on Oct 28, 2024Recent Insider Transactions • Oct 01Chief Financial Officer recently sold ₹33m worth of stockOn the 27th of September, Suhas Prabhu sold around 50k shares on-market at roughly ₹669 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suhas' only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹675, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 46x in the Life Sciences industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹273 per share.공고 • Aug 07Indegene Limited, Annual General Meeting, Sep 06, 2024Indegene Limited, Annual General Meeting, Sep 06, 2024, at 16:30 Indian Standard Time.Reported Earnings • Aug 02First quarter 2025 earnings released: EPS: ₹3.79 (vs ₹3.09 in 1Q 2024)First quarter 2025 results: EPS: ₹3.79 (up from ₹3.09 in 1Q 2024). Revenue: ₹6.99b (up 9.9% from 1Q 2024). Net income: ₹877.0m (up 28% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.공고 • Jul 25Indegene Limited to Report Q1, 2025 Results on Aug 01, 2024Indegene Limited announced that they will report Q1, 2025 results on Aug 01, 2024공고 • May 23Indegene Limited to Report Q4, 2024 Results on May 29, 2024Indegene Limited announced that they will report Q4, 2024 results on May 29, 2024이익 및 매출 성장 예측BSE:544172 - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/202956,8847,7217,4867,81323/31/202848,3746,5026,8307,67553/31/202742,9475,1774,8156,25353/31/202635,1054,0116,0656,508N/A12/31/202532,6274,390N/AN/AN/A9/30/202530,4104,4584,6835,094N/A6/30/202529,2364,354N/AN/AN/A3/31/202528,3934,0674,1194,419N/A12/31/202427,5673,839N/AN/AN/A9/30/202427,0973,7304,3024,377N/A6/30/202426,5863,560N/AN/AN/A3/31/202425,8963,3674,9705,077N/A12/31/202325,4892,9073,8714,100N/A6/30/202323,9272,487N/AN/AN/A3/31/202323,0612,6611,1141,302N/A3/31/202216,6461,6482,7232,970N/A3/31/20219,8061,8571,5141,720N/A3/31/20206,436558162223N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 544172 의 연간 예상 수익 증가율(21.3%)이 saving rate(6.9%)보다 높습니다.수익 vs 시장: 544172 의 연간 수익(21.3%)이 Indian 시장(16.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 544172 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 544172 의 수익(연간 15.1%)이 Indian 시장(연간 11.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 544172 의 수익(연간 15.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 544172의 자본 수익률은 3년 후 16.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 03:25종가2026/07/23 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Indegene Limited는 14명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null null360 ONE Capital Market Private LimitedDeep Shah360 ONE Capital Market Private LimitedRajiv BerliaCitigroup Inc11명의 분석가 더 보기
Reported Earnings • Jul 19Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.72 (down from ₹17.15 in FY 2025). Revenue: ₹35.1b (up 24% from FY 2025). Net income: ₹4.01b (down 1.4% from FY 2025). Profit margin: 11% (down from 14% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
공고 • Jul 16+ 1 more updateIndegene Limited, Annual General Meeting, Aug 13, 2026Indegene Limited, Annual General Meeting, Aug 13, 2026, at 16:30 Indian Standard Time.
공고 • Jul 10Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026
공고 • Apr 21Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026
Reported Earnings • Jan 30Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
공고 • Jan 22Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026
Buy Or Sell Opportunity • Nov 24Now 21% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₹515. The fair value is estimated to be ₹426, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last year. Earnings per share has grown by 14%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 27% in the next 2 years.
Reported Earnings • Nov 01Second quarter 2026 earnings released: EPS: ₹4.26 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.26 (up from ₹3.84 in 2Q 2025). Revenue: ₹8.24b (up 20% from 2Q 2025). Net income: ₹1.02b (up 11% from 2Q 2025). Profit margin: 12% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
공고 • Oct 23Indegene Limited to Report Q2, 2026 Results on Oct 30, 2025Indegene Limited announced that they will report Q2, 2026 results on Oct 30, 2025
Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Non-Executive Independent Director Georgia Papathomas was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Aug 03First quarter 2026 earnings released: EPS: ₹4.86 (vs ₹3.79 in 1Q 2025)First quarter 2026 results: EPS: ₹4.86 (up from ₹3.79 in 1Q 2025). Revenue: ₹7.61b (up 13% from 1Q 2025). Net income: ₹1.16b (up 33% from 1Q 2025). Profit margin: 15% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
공고 • Jul 24Indegene Limited to Report Q1, 2026 Results on Jul 31, 2025Indegene Limited announced that they will report Q1, 2026 results on Jul 31, 2025
공고 • Jun 06An undisclosed buyer agreed to acquire an unknown minority stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments.An undisclosed buyer agreed to acquire 10.19% stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments on June 3, 2025. The expected date of completion is June 06, 2025.
Reported Earnings • Jun 01Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
공고 • May 29Indegene Limited, Annual General Meeting, Jun 26, 2025Indegene Limited, Annual General Meeting, Jun 26, 2025, at 16:30 Indian Standard Time.
Reported Earnings • May 02Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
New Risk • Apr 30New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
공고 • Apr 21Indegene Limited to Report Q4, 2025 Results on Apr 28, 2025Indegene Limited announced that they will report Q4, 2025 results on Apr 28, 2025
공고 • Feb 25Indegene Launches Cortex, A Fit-For-Purpose Generative Ai PlatformIndegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry Bengaluru, India and Princeton, US, February 24, 2025: Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement.
Reported Earnings • Jan 31Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹4.59 (up from ₹4.45 in 3Q 2024). Revenue: ₹7.58b (up 10% from 3Q 2024). Net income: ₹1.10b (up 11% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 2.2%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
Recent Insider Transactions • Dec 29Chairman & CEO recently bought ₹10m worth of stockOn the 24th of December, Manish Gupta bought around 17k shares on-market at roughly ₹599 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹60m. This was Manish's only on-market trade for the last 12 months.
Recent Insider Transactions • Dec 20Non-Executive Director recently bought ₹60m worth of stockOn the 17th of December, Rajesh Nair bought around 100k shares on-market at roughly ₹596 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹14m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Dec 07Insider recently sold ₹13m worth of stockOn the 5th of December, Viveksheel Ghai sold around 20k shares on-market at roughly ₹628 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹33m. Insiders have been net sellers, collectively disposing of ₹46m more than they bought in the last 12 months.
Reported Earnings • Oct 29Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹3.84. Net income: ₹917.0m (up ₹917.0m from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
공고 • Oct 23Indegene Limited to Report Q2, 2025 Results on Oct 28, 2024Indegene Limited announced that they will report Q2, 2025 results on Oct 28, 2024
Recent Insider Transactions • Oct 01Chief Financial Officer recently sold ₹33m worth of stockOn the 27th of September, Suhas Prabhu sold around 50k shares on-market at roughly ₹669 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suhas' only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹675, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 46x in the Life Sciences industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹273 per share.
공고 • Aug 07Indegene Limited, Annual General Meeting, Sep 06, 2024Indegene Limited, Annual General Meeting, Sep 06, 2024, at 16:30 Indian Standard Time.
Reported Earnings • Aug 02First quarter 2025 earnings released: EPS: ₹3.79 (vs ₹3.09 in 1Q 2024)First quarter 2025 results: EPS: ₹3.79 (up from ₹3.09 in 1Q 2024). Revenue: ₹6.99b (up 9.9% from 1Q 2024). Net income: ₹877.0m (up 28% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.
공고 • Jul 25Indegene Limited to Report Q1, 2025 Results on Aug 01, 2024Indegene Limited announced that they will report Q1, 2025 results on Aug 01, 2024
공고 • May 23Indegene Limited to Report Q4, 2024 Results on May 29, 2024Indegene Limited announced that they will report Q4, 2024 results on May 29, 2024